Preparation method of NK (Natural Killer) cells and application of pharmaceutical composition of NK cells in cancer treatment

The combined application of NK cells produced by iPSC differentiation and their exosomes and HER2-VNAR solves the problems of low efficiency and insufficient specificity of NK cells in vitro expansion, and achieves efficient and low-cost tumor treatment, and HER2-VNAR The activity is better than that of commercial antibodies.

CN119055757AInactive Publication Date: 2024-12-03广州兴牧生物医药技术有限公司
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411238836.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-05
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In tumor therapy, the in vitro amplification technology of NK cells is inefficient, costly, and insufficient specificity and safety, and the combination of existing therapies with other immunotherapies or traditional therapies are challenging.

Method used

Using the pharmaceutical composition of NK cells and their exosomes and HER2-VNAR produced by iPSC differentiation, the targeted tumor treatment of NK cells is improved through the combined application of iPSC-NK cells, iPSC-NK cell exosomes and HER2-VNAR. Effect.

Benefits of technology

Large-scale production and storage of NK cells is achieved, production costs are reduced, efficiency and specificity of tumor treatment are improved, side effects are reduced, and the activity of HER2-VNAR is better than that of commercial HER2 monoclonal antibodies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055757A_ABST
    Figure CN119055757A_ABST
Patent Text Reader

Abstract

The invention discloses a pharmaceutical composition, and the pharmaceutical composition comprises four kinds, specifically as follows: a first kind of pharmaceutical composition, which contains iPSC-NK cells, a second kind of pharmaceutical composition, a third kind of pharmaceutical composition, a fourth kind of pharmaceutical composition and a fifth kind of pharmaceutical composition, the second medicine composition is prepared from an iPSC-NK cell and an iPSC-NK cell exosome; the third medicine composition is prepared from the iPSC-NK cells and the HER2-VNAR; and the fourth medicine composition is prepared from the iPSC-NK cell, the iPSC-NK cell exosome and the HER2-VNAR. The pharmaceutical composition disclosed by the invention has a good treatment effect on tumors, and provides a good reference for researches on application of NK cells and NK cell exosomes in tumor treatment and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and specifically relates to a method for preparing NK cells and use of a pharmaceutical composition thereof in treating cancer. Background Art

[0002] NK cells, full name Natural Killer cells, are an important cell type in the immune system and are part of innate immunity. They play a key role in fighting tumors and viral infections. NK cells are generated in the bone marrow and migrate to the blood and tissues after maturation, where they play an important role. Their main functions include the following:

[0003] (1) Direct killing: NK cells can recognize and directly kill virus-infected cells or tumor cells.

[0004] (2) Immune regulation: NK cells regulate immune responses by secreting cytokines (such as interferon-γ and tumor necrosis factor-α).

[0005] (3) Antibody-dependent cell-mediated cytotoxicity (ADCC): NK cells recognize and bind to antibody-coated target cells through the CD16 receptor on their surface, thereby killing these cells.

[0006] In addition, NK cells also have many applications in tumor treatment, mainly including the following points:

[0007] (1) NK cell adoptive transfer: NK cells are separated from the patient, expanded in vitro, and then returned to the patient to enhance their anti-tumor ability.

[0008] (2) CAR-NK cells: Chimeric antigen receptors (CARs) are introduced into NK cells through genetic engineering to enhance their ability to recognize and kill specific tumor antigens.

[0009] (3) Bispecific antibodies: Bispecific or trispecific antibodies are used to simultaneously bind to NK cells and tumor cells, thereby enhancing the tumor-killing ability of NK cells.

[0010] The research and application of NK cells are developing rapidly, and their potential in cancer treatment and immune regulation is constantly being explored and verified. With the advancement of science, NK cells are expected to become one of the important means of tumor treatment in the future. Although NK cells have powerful anti-tumor functions in theory, there are still many challenges in practical application:

[0011] (1) In vitro expansion: The in vitro expansion technology of NK cells is the key to its clinical application and needs to be optimized to improve efficiency and cost-effectiveness.

[0012] (2) Specificity and safety: Improving the specificity of NK cells and reducing side effects are the current research focuses.

[0013] (3) Combination therapy: The combined use of NK cell therapy with other immunotherapies or traditional cancer treatments may improve the therapeutic effect. Summary of the invention

[0014] In order to make up for the deficiencies of the prior art, the object of the present invention is to provide a method for preparing NK cells and use of a pharmaceutical composition thereof in treating cancer.

[0015] In one aspect, the present invention discloses a pharmaceutical composition, which includes 4 types, as follows:

[0016] The first pharmaceutical composition comprises iPSC-NK cells;

[0017] The second pharmaceutical composition comprises iPSC-NK cells and iPSC-NK cell exosomes;

[0018] The third pharmaceutical composition: comprising iPSC-NK cells and HER2-VNAR;

[0019] The fourth pharmaceutical composition: comprises iPSC-NK cells, iPSC-NK cell exosomes and HER2-VNAR.

[0020] Preferably, the amino acid sequence of the HER2-VNAR of the present invention is as shown in SEQ ID NO.1.

[0021] Preferably, the codon-optimized nucleotide sequence of the HER2-VNAR of the present invention is as shown in SEQ ID NO.2.

[0022] Preferably, the iPSC-NK cells in the first pharmaceutical composition of the present invention are diluted with physiological saline when used.

[0023] Preferably, the iPSC-NK cells in the second pharmaceutical composition of the present invention are diluted with iPSC-NK cell exosomes when used.

[0024] Preferably, the iPSC-NK cells and HER2-VNAR in the third pharmaceutical composition described in the present invention are diluted with physiological saline when used.

[0025] Preferably, the iPSC-NK cells and HER2-VNAR in the fourth pharmaceutical composition described in the present invention are diluted with iPSC-NK cell exosomes when used.

[0026] In another aspect, the present invention also discloses a use of the HER2-VNAR in preparing a drug for treating tumors.

[0027] In another aspect, the present invention also discloses a use of the pharmaceutical composition in preparing a drug for treating tumors.

[0028] Preferably, the tumors described in the present invention include breast cancer, gastric cancer, non-small cell lung cancer, ovarian cancer, bile duct cancer, and endometrial cancer.

[0029] The NK cells (iPSC-NK cells) produced by iPSC differentiation in the present invention have many advantages. First, mature cell reprogramming technology can ensure the stability of the source of iPSC, the uniformity of cells, and does not rely on a specific donor. Secondly, iPSC can be expanded on a large scale, which is conducive to the mass production and storage of NK cells, reducing production costs and shortening the time from preparation to use. Finally, compared with primary NK cells, iPSC is easier to perform gene editing and viral infection, thereby preparing a variety of gene-modified iPSC cell lines to meet the needs of different tumor treatments.

[0030] At the same time, the present invention prepared exosomes of iPSC-NK cells and single-domain antibodies of HER2 on the basis of iPSC-NK cells, and studied the combined application of the three. It was found that the combined application of the three had a good therapeutic effect on targeted tumors. This provides a good reference for the research on NK cells, exosomes and single-domain antibodies in the treatment of tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 Electron microscopy results of exosomes.

[0032] Figure 2 Exosome western blot results.

[0033] Figure 3 SDS-PAGE detection results of HER2-VNAR.

[0034] Figure 4 The therapeutic results of iPSC-NK cells and their exosomes in nude mice. DETAILED DESCRIPTION

[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0036] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0037] Example 1: Preparation of iPSC-NK cells

[0038] 1. Materials and equipment: induced pluripotent stem cells (iPSC); culture medium: basal culture medium (such as DMEM / F12), NK cell-specific culture medium, cytokines (such as IL-2, IL-15, IL-21, FLT3-L, SCF); culture containers: culture bottles, cell culture plates, cell culture bags; centrifuge, CO2 incubator; flow cytometer; sterile operating table, etc.

[0039] 2. Maintenance and expansion of iPSCs: (1) Maintain iPSCs in culture flasks coated with Matrigel or similar matrix using mTeSR1 or similar medium. (2) Replace fresh medium daily, observe cell morphology, and maintain the cells in a typical pluripotent stem cell morphology. (3) When the cells are close to 90% confluence, use cell separation agents such as EDTA to separate the cells for passaging or differentiation experiments.

[0040] 3. Differentiation induction: (1) Collect iPSCs, replace the basal medium with NK cell differentiation medium (containing hematopoietic stem cell support factors such as SCF and FLT3-L) to start inducing differentiation. (2) After 2-3 days, add NK cell growth factors such as IL-15 and IL-21 to promote NK cell-specific differentiation. (3) Continue to monitor cell morphology changes and replace the medium in a timely manner according to cell density.

[0041] 4. Cell expansion: (1) Differentiated NK cells enter a rapid proliferation phase and continue to be cultured using NK cell culture medium enriched with IL-2 and IL-15. (2) Replace the culture medium every 2-3 days, monitor cell growth and status, and adjust the cell density as appropriate.

[0042] 5. Cell collection and purification: (1) Detect and collect NK cells using flow cytometry and specific markers (such as CD56+CD3-). (2) Perform functional verification on the collected NK cells.

[0043] 6. Cell cryopreservation: Adjust the qualified NK cells (referred to as iPSC-NK cells) to a suitable density (usually 1×10^6 cells / ml) in a cryopreservation solution containing 10% DMSO. Gradually cool to -80°C in a controlled cooling device, and then transfer to a liquid nitrogen tank for long-term storage.

[0044] Example 2: Preparation of iPSC-NK cell exosomes

[0045] 1. iPSC-NK cell culture:

[0046] 1.1 Prepare exosome-depleted FBS (by ultracentrifugation, 100,000 × g, 18 h, 4°C).

[0047] 1.2 The iPSC-NK cells prepared in Example 1 were inoculated in an appropriate culture medium (such as RPMI-1640) containing exosome-removed FBS.

[0048] 1.3 The cell density should be controlled at 0.5-1×10^6 cells / mL and cultured in a 37℃, 5% CO2 incubator.

[0049] 2. Cell culture and exosome secretion:

[0050] 2.1 When the cells grow to the logarithmic growth phase (about 5-7 days), collect the cell culture supernatant.

[0051] 2.2 Remove cells and large cell debris by low-speed centrifugation (300×g, 10 minutes).

[0052] 2.3 Transfer the supernatant to a new centrifuge tube and centrifuge at 2000×g for 20 minutes to remove residual cell debris.

[0053] 2.4 Transfer the supernatant to a new centrifuge tube and centrifuge at 10,000 × g for 30 minutes to remove larger vesicles and debris.

[0054] 3. Exosome isolation:

[0055] 3.1 The supernatant was filtered through a 0.22 μm filter to remove particles.

[0056] 3.2 Using ultracentrifugation:

[0057] (1) The filtered supernatant was ultracentrifuged at 100,000 × g for 70 min at 4°C.

[0058] (2) Carefully discard the supernatant and retain the precipitate (exosomes).

[0059] (3) The precipitate was resuspended in ice-cold PBS and ultracentrifuged again (100,000 × g, 70 min, 4°C) to wash the exosomes.

[0060] (4) Repeat the cleaning step 2-3 times.

[0061] 4. Exosome identification:

[0062] 4.1 Confirm the size and morphology of exosomes using nanoparticle tracking analysis (NTA) or transmission electron microscopy (TEM). Figure 1 shown.

[0063] 4.2 Use Western Blot to detect exosome markers (such as CD9, CD63, CD81, TSG101, etc.). Figure 2 shown.

[0064] 5. Exosome preservation:

[0065] 5.1 After resuspending, the exosomes can be used immediately or stored at -80℃.

[0066] 5.2 During long-term storage, it is recommended to add a protective agent (such as DMSO) to improve the stability of exosomes.

[0067] Example 3: Preparation of HER2 single domain antibody

[0068] 1. Recombinant human HER2 protein (MCE, HY-P73094) was diluted to 20 μg / ml with shark physiological saline, and the diluted antigen was mixed with adjuvant in a ratio of 1:1 for emulsification. Immunization was performed by intraperitoneal injection. Freund's complete adjuvant was used for the first immunization, and Freund's incomplete adjuvant was used for subsequent immunizations. A total of 3 immunizations were performed, with injections every two weeks.

[0069] 2. Take the immunized shark serum for transcriptome sequencing to analyze the antibody production in the shark, and extract the spleen and lymphocyte RNA of the immunized shark for RT-PCR to obtain a high-throughput database containing only shark VNAR. Compare the obtained transcriptome high-throughput sequencing results with the high-throughput database of VNAR, and screen the sequences that are contained in both databases and have a high content. The VNAR sequence obtained in combination with the screening results is shown in SEQ ID NO.1, which is a single-domain antibody of HER2 protein (labeled as HER2-VNAR).

[0070] 3. Codon optimization was performed on HER2-VNAR, and the optimized nucleotides were subcloned into the Nco I and Xho I sites of pET28a, and 6His was added to the C-terminus to facilitate purification, thereby obtaining pET28a-HER2-VNAR. The nucleotide sequence of the codon-optimized HER2-VNAR is shown in SEQ ID NO.2.

[0071] 4. Transform the pET28a-HER2-VNAR plasmid into BL21 (DE3) competent cells, spread on LB agar plates containing kanamycin, and culture at 36-37°C at a constant temperature for 16-20 hours. Pick a single colony from the plate and inoculate it into 3 ml of LB medium containing kanamycin, and culture it at 36-37°C at 220-240 r / min with shaking until the OD600nm value reaches 0.4-0.6. Harvest part of the bacterial solution and add sterile glycerol to a final concentration of 25% for storage.

[0072] 5. Take the bacterial solution and culture it at 37℃, then cool it to 20℃, induce expression with IPTG, and collect the bacteria; resuspend the bacteria, crush them, collect the supernatant by centrifugation, purify them with nickel column and dialyze them, and filter and sterilize them with 0.22μm low protein adsorption filter membrane to obtain HER2-VNAR. The content of purified HER2-VNAR was 2.15mg / ml by BCA detection, and the SDS-PAGE detection results were as follows Figure 3 As shown, its expression level is about 268 mg / L.

[0073] This study compared the activity of HER2-VNAR and commercial HER2 monoclonal antibody (ab134182), and found that the activity of HER2-VNAR prepared by the present invention is better than that of commercial HER2 monoclonal antibody.

[0074] Example 4: Application of iPSC-NK cells and exosomes thereof

[0075] First, breast cancer cells MCF7, gastric cancer cells SGC7901, non-small cell lung cancer cells A549, ovarian cancer cells PE04, bile duct cancer cells QBC939, and endometrial cancer cells RL95-2 were cultured and made into cell suspensions. Then, the same number (10 6 The different cells of each group were resuspended in 200 μL of saline and injected subcutaneously into the back of BALA / C nude mice (5-6 weeks old). The formation and growth of tumors were observed and recorded regularly. When the tumor was clearly visible, the size of the tumor was observed and measured every day. When the tumor grew to 80 mm 3 At about 1:10 pm, 30 nude mice with good growth status and uniform tumor size were selected from each group of cells and randomly divided into 6 groups, 5 mice in each group. All nude mice were killed after 4 weeks of treatment. The subcutaneous tumors of the killed nude mice were removed, weighed and recorded. The specific groups and treatments are shown in Table 1.

[0076] Table 1 Summary of nude mouse treatment groups and treatment status

[0077]

[0078] The results show that Figure 4 ), group 5 had the best effect, group 3 was slightly better than group 4, but better than group 1 and group 2, and group 2 was better than group 1. The above results show that the iPSC-NK cells prepared by the present invention have better effects than NK cells prepared by conventional methods, and the exosomes prepared thereby have a good promoting effect on iPSC-NK cells; at the same time, the HER2-VNAR prepared by the present invention also has a good promoting effect on iPSC-NK cells, and the combined use of exosomes, HER2-VNAR and iPSC-NK cells has the best effect.

[0079] It should be noted that the present invention uses a commercial HER2 monoclonal antibody (ab134182) to replace the HER2-VNAR in Group 4, and it is found that its effect is not as good as the HER2-VNAR of the present invention. This may be because the commercial HER2 monoclonal antibody has a larger molecular weight. After the second injection, the body is prone to produce antibodies against the commercial HER2 monoclonal antibody, thereby inhibiting its effect!

[0080] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A pharmaceutical composition, characterized in that The pharmaceutical compositions are: The first pharmaceutical composition: comprising iPSC-NK cells; The second pharmaceutical composition comprises iPSC-NK cells and iPSC-NK cell exosomes; The third pharmaceutical composition: comprising iPSC-NK cells and HER2-VNAR; The fourth pharmaceutical composition: comprises iPSC-NK cells, iPSC-NK cell exosomes and HER2-VNAR.

2. The pharmaceutical composition according to claim 1, characterized in that The amino acid sequence of the HER2-VNAR is shown in SEQ ID NO.

1.

3. The pharmaceutical composition according to claim 1, characterized in that The nucleotide sequence of the HER2-VNAR after codon optimization is shown in SEQ ID NO.

2.

4. The pharmaceutical composition according to claim 1, characterized in that The iPSC-NK cells in the first pharmaceutical composition are diluted with physiological saline when used.

5. The pharmaceutical composition according to claim 1, characterized in that The iPSC-NK cells in the second pharmaceutical composition are diluted with iPSC-NK cell exosomes when used.

6. The pharmaceutical composition according to claim 1, characterized in that The iPSC-NK cells and HER2-VNAR in the third pharmaceutical composition are diluted with physiological saline when used.

7. The pharmaceutical composition according to claim 1, characterized in that The iPSC-NK cells and HER2-VNAR in the fourth pharmaceutical composition are diluted with iPSC-NK cell exosomes when used.

8. Use of the HER2-VNAR according to claim 1 in preparing a drug for treating tumors.

9. Use of the pharmaceutical composition according to claim 1 in preparing a drug for treating tumors.

10. The use according to any one of claims 8 or 9, characterized in that: The tumors include breast cancer, gastric cancer, non-small cell lung cancer, ovarian cancer, bile duct cancer, and endometrial cancer.

Citation Information

Cited By

  • Preparation method of CART cell and application of CART cell in anti-tumor treatment

    CN120209163A

  • A method for preparing CART cells and its application in anti-tumor treatment

    CN120209163B